Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1629686

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1629686

Cardiogenic Shock Treatment Market, By Treatment Type, By End User, By Geography

PUBLISHED:
PAGES: 161 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The global cardiogenic shock treatment market is estimated to be valued at USD 1.10 Bn in 2024 and is expected to reach USD 1.78 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 1.10 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 7.10% 2031 Value Projection: US$ 1.78 Bn
Figure. Cardiogenic Shock Treatment Market Share (%), By Region 2024
Cardiogenic Shock Treatment Market - IMG1

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's need. This failure can result from conditions like heart attack, complications after heart surgery, or heart muscle infection. Without prompt treatment it can rapidly lead to organ dysfunction and death. Globally rising cases of cardiovascular diseases and increasing demand for effective management of complex cardiac conditions are the major factors anticipated to boost the growth of the cardiogenic shock treatment market worldwide in the coming years.

Market Dynamics:

The global cardiogenic shock treatment market is primarily driven by the increasing prevalence of cardiovascular diseases such as coronary artery disease, heart attacks, and heart failures. According to the World Health Organization, in June 2021, cardiovascular diseases are the leading cause of deaths globally, taking an estimate of over 17.9 million lives each year. Moreover, rising geriatric population susceptible to develop such critical cardiac conditions also supports the market growth. Various technological advancements in mechanical circulatory support devices and rapid adoption of these effective management options offer new opportunities. However, high cost associated with devices and surgical procedures hampers market penetration in low-income regions. Additionally, lack of awareness among people about early diagnosis and management options pose challenges.

Key Features of the Study:

This report provides in-depth analysis of the global cardiogenic shock treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global cardiogenic shock treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global cardiogenic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiogenic shock treatment market

Market Segmentation

  • Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Mechanical Support Devices
    • Pharmacological Treatments:
    • Surgical Procedures
    • Others
  • End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospitals
    • Cardiac Care Centers
    • Ambulatory Surgical Centers
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Abbott
    • Medtronic
    • Getinge AB
    • Abiomed
    • Terumo Corporation
    • Boston Scientific
    • F.Hoffmann-La Roche Ltd
    • Bayer AG
    • Viatris Inc.
    • Par Pharmaceutical
    • AstraZeneca
    • Zoll Medical Corporation
    • Xenios AG (part of Fresenius Medical Care)
    • Windtree Therapeutics
    • Chiesi Farmaceutici S.p.A.
Product Code: CMI7535

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Cardiogenic Shock Treatment Market, By Treatment Type
    • Global Cardiogenic Shock Treatment Market, By End User
    • Global Cardiogenic Shock Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Cardiogenic Shock Treatment Market, By Treatment Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Mechanical Support Devices
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Pharmacological Treatments:
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Surgical Procedures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Cardiogenic Shock Treatment Market, By End User, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Cardiac Care Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Cardiogenic Shock Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

7. Competitive Landscape

  • Abbott
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Medtronic
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Getinge AB
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abiomed
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Terumo Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boston Scientific
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F.Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Par Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zoll Medical Corporation
  • Xenios AG (part of Fresenius Medical Care)
  • Windtree Therapeutics
  • Chiesi Farmaceutici S.p.A.

8. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

9. References and Research Methodology

  • References
  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!